How does age determine the development of human immune-mediated arthritis?

Degboé, Yannick; Vastert, Sebastiaan J.; Prakken, Berent J.; McInnes, Iain B.

doi:10.1038/s41584-022-00814-3

Cited by 8 publications

(5 citation statements)

References 173 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…JIA has been classified into several subtypes, including systemic, oligoarticular, and polyarticular JIA, psoriatic arthritis, and enthesitis-related JIA, with its occasional subdivision into negative and positive RF forms [1,7,30]. The present patient was clinically defined as having polyarticular JIA, RF-negative.…”

Section: Discussionmentioning

confidence: 90%

Genome Sequencing in an Individual Presenting with 22q11.2 Deletion Syndrome and Juvenile Idiopathic Arthritis

de Oliveira-Sobrinho,

Appenzeller,

Holanda

et al. 2024

Genes

View full text Add to dashboard Cite

Juvenile idiopathic arthritis is a heterogeneous group of diseases characterized by arthritis with poorly known causes, including monogenic disorders and multifactorial etiology. 22q11.2 proximal deletion syndrome is a multisystemic disease with over 180 manifestations already described. In this report, the authors describe a patient presenting with a short stature, neurodevelopmental delay, and dysmorphisms, who had an episode of polyarticular arthritis at the age of three years and eight months, resulting in severe joint limitations, and was later diagnosed with 22q11.2 deletion syndrome. Investigation through Whole Genome Sequencing revealed that he had no pathogenic or likely-pathogenic variants in both alleles of the MIF gene or in genes associated with monogenic arthritis (LACC1, LPIN2, MAFB, NFIL3, NOD2, PRG4, PRF1, STX11, TNFAIP3, TRHR, UNC13DI). However, the patient presented 41 risk polymorphisms for juvenile idiopathic arthritis. Thus, in the present case, arthritis seems coincidental to 22q11.2 deletion syndrome, probably caused by a multifactorial etiology. The association of the MIF gene in individuals previously described with juvenile idiopathic arthritis and 22q11.2 deletion seems unlikely since it is located in the distal and less-frequently deleted region of 22q11.2 deletion syndrome.

show abstract

Section: Discussionmentioning

confidence: 90%

Genome Sequencing in an Individual Presenting with 22q11.2 Deletion Syndrome and Juvenile Idiopathic Arthritis

de Oliveira-Sobrinho,

Appenzeller,

Holanda

et al. 2024

Genes

View full text Add to dashboard Cite

show abstract

“…Given the underlying inflammatory nature of PsA upon its onset, PsA could promote or exacerbate the pre-existing age-related cardiovascular risk. On the other hand, it has been proposed that pro-inflammatory conditions such as adiposity, smoking, microbiome dysbiosis, immunosenescence, and “inflammageing”, as well as comorbidity-related drivers that may lead to a break in tolerance and to the corollary initiation of autoimmune inflammatory diseases later in life [ 12 ]. However, a lot of research is still required to fuel these theories.…”

Section: Discussionmentioning

confidence: 99%

“…Given the advancing aging of the population, the diagnosis of PsA in older individuals is becoming more prevalent in daily clinical practice [ 11 , 12 ]. In parallel, the management of PsA in this subgroup seems to be more complicated by the multimorbidity and the polypharmacy burden that comes along with this, in addition to the altered pharmacokinetics and/or pharmacodynamics [ 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Late-Onset Psoriatic Arthritis: Are There Any Distinct Characteristics? A Retrospective Cohort Data Analysis

Gialouri

Evangelatos

Iliopoulos

et al. 2023

Life

View full text Add to dashboard Cite

As life expectancy increases, psoriatic arthritis (PsA) in older individuals becomes more prevalent. We explored whether late-onset versus earlier-onset PsA patients display different clinical features at diagnosis and/or during the disease course, as well as different treatment approaches and comorbidity profiles. We retrospectively collected data from consecutive PsA patients attending two rheumatology centers (December 2017–December 2022). Late-onset PsA patients (diagnosis-age: ≥60 years) were compared to those diagnosed before 60 years old. Univariate analyses and logistic regression were performed to examine for factors associated with late-onset PsA. For sensitivity analyses, the cohort’s mean diagnosis age was used as the cut-off value. Overall, 281 PsA patients were included (mean ± SD diagnosis-age: 46.0 ± 13.3 years). Of them, 14.2% (N = 40) had late-onset PsA. At diagnosis, after controlling for confounders, no demographic and clinical differences were identified. During the disease course, the late-onset group exhibited 65% fewer odds of manifesting enthesitis (adjusted Odds-ratio—adOR 0.35; 95% confidence interval 0.13–0.97), but higher frequency of dyslipidemia (adOR 3.01; 1.30–6.95) and of major adverse cardiovascular events (adOR 4.30; 1.42–12.98) compared to earlier-onset PsA group. No differences were found in the treatment approaches. In sensitivity analyses, PsA patients diagnosed after 46 (vs. ≤46) years old had an increased frequency of hypertension (adOR 3.18; 1.70–5.94) and dyslipidemia (adOR 2.17; 1.25–3.74). The present study underpins that late-onset PsA is not uncommon, while the age at PsA onset may affect the longitudinal clinical expression of the disease. Patients with late-onset PsA were less likely to manifest enthesitis but displayed increased cardiovascular risk.

show abstract

“…Comorbid conditions are increasingly recognized to play a critical role in treating RA [ 10 ]. Comorbidities can influence disease activity, treatment response, functional impairment, and quality of life in patients [ 11 ]. Cardiovascular diseases, metabolic syndrome, respiratory comorbidities, osteoporosis, and mental health disorders are commonly observed as comorbid conditions in RA [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Comorbidities Among Individuals With Rheumatoid Arthritis in the Saudi Arabian Context

Alghamdi,

Somaily,

Alemam

et al. 2024

Cureus

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) in Saudi Arabia (SA) is a significant health concern with a notable impact on individuals and the healthcare system. This study aimed to investigate the prevalence and profile of comorbidities in patients with RA. Methodology: This is a retrospective descriptive study involving 150 RA patients from August 2022 to August 2023, which was conducted at Khamis Mushait General Hospital, a major healthcare institution in SA. We examined the medical records to gather pertinent information. Stata Statistical Software: Release 18 (2023; StataCorp LLC, College Station, Texas, United States) was used for data analysis. The examination focused on sociodemographic factors, disease duration, prescribed medications (including methotrexate and biologic therapy), and the presence of comorbidities. Approval for the study was obtained from the Institutional Review Board of the Aseer Ministry of Health (approval number: H-06-B-091). Results: The study found a high prevalence of comorbidities in patients with RA. Around 96.7% of the patients had at least one documented comorbidity, highlighting this population's burden of additional health conditions. The most common comorbidity observed was anemia, affecting 48.7% of the patients. Other frequently observed comorbidities include hypertension, hyperlipidemia, diabetes mellitus, osteoporosis, interstitial lung disease, chronic renal disease, stroke, and coronary artery disease. The factors influencing comorbidities included an odds ratio of 1.086 (p=0.025), while being male was associated with lower odds (odds ratio=0.529, p=0.017). Additionally, disease duration (odds ratio=1.164, p=0.007), methotrexate use (odds ratio=2.553, p=0.001), and receiving biologic therapy (odds ratio=3.488, p<0.001) were significant contributors to comorbidities. Conclusion: These findings highlight the need for comprehensive approaches to address RA and its associated comorbidities. Research and awareness initiatives are essential to understand better the specific nuances of RA in SA, leading to improved diagnostic and treatment strategies for the needs of the local population.

show abstract

How does age determine the development of human immune-mediated arthritis?

Cited by 8 publications

References 173 publications

Genome Sequencing in an Individual Presenting with 22q11.2 Deletion Syndrome and Juvenile Idiopathic Arthritis

Genome Sequencing in an Individual Presenting with 22q11.2 Deletion Syndrome and Juvenile Idiopathic Arthritis

Late-Onset Psoriatic Arthritis: Are There Any Distinct Characteristics? A Retrospective Cohort Data Analysis

Prevalence and Comorbidities Among Individuals With Rheumatoid Arthritis in the Saudi Arabian Context

Contact Info

Product

Resources

About